智通财经APP获悉，Organovo Holdings今日宣布，礼来(LLY.US)（Eli Lilly and Company）将收购该公司旗下的FXR项目及主打疗法FXR314。FXR314是一款潜在“best-in-class ...

（原标题：礼来(LLY.US)收购Organovo旗下FXR项目及主打疗法FXR314 用于治疗溃疡性结肠炎） 智通财经APP获悉，Organovo Holdings今日宣布，礼来(LLY.US)（Eli Lilly ...

“We are excited to deliver FXR314 and our FXR program to Lilly for Phase 2 and further development. Their world-class development excellence and dedication to delivering for patients will ...

Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease (IBD), in a deal worth up to $50 million in biobucks. Organovo’s stock ...